Nexthera Capital LP lessened its position in shares of FibroGen Inc (NASDAQ:FGEN) by 24.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 150,888 shares of the biopharmaceutical company’s stock after selling 49,953 shares during the quarter. FibroGen comprises 1.1% of Nexthera Capital LP’s investment portfolio, making the stock its 24th biggest holding. Nexthera Capital LP owned about 0.18% of FibroGen worth $6,971,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. Bank of Montreal Can grew its position in FibroGen by 2,097.2% during the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 3,041 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in FibroGen by 41.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 1,147 shares during the period. Aperio Group LLC acquired a new position in shares of FibroGen during the first quarter worth about $207,000. Paloma Partners Management Co acquired a new position in shares of FibroGen during the fourth quarter worth about $255,000. Finally, Gideon Capital Advisors Inc. acquired a new position in shares of FibroGen during the first quarter worth about $332,000. Hedge funds and other institutional investors own 63.07% of the company’s stock.
Shares of NASDAQ FGEN opened at $62.60 on Friday. FibroGen Inc has a 1 year low of $31.35 and a 1 year high of $65.00. The firm has a market cap of $5.16 billion, a price-to-earnings ratio of -36.18 and a beta of 1.95. The company has a debt-to-equity ratio of 0.19, a current ratio of 8.61 and a quick ratio of 8.61.
FibroGen (NASDAQ:FGEN) last released its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.01. The company had revenue of $31.90 million during the quarter, compared to analyst estimates of $29.07 million. FibroGen had a negative return on equity of 27.70% and a negative net margin of 102.86%. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.48) earnings per share. equities research analysts forecast that FibroGen Inc will post -1.58 earnings per share for the current year.
In other news, SVP Pat Cotroneo sold 14,987 shares of the firm’s stock in a transaction dated Monday, May 21st. The stock was sold at an average price of $55.04, for a total value of $824,884.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Thomas B. Neff sold 39,636 shares of the firm’s stock in a transaction dated Thursday, June 21st. The shares were sold at an average price of $63.62, for a total value of $2,521,642.32. Following the completion of the sale, the chief executive officer now directly owns 2,856,353 shares in the company, valued at $181,721,177.86. The disclosure for this sale can be found here. Insiders sold 311,818 shares of company stock worth $16,320,411 over the last ninety days. 8.96% of the stock is currently owned by company insiders.
Several research analysts recently commented on the company. Zacks Investment Research cut FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Mizuho restated a “hold” rating and set a $61.00 price objective on shares of FibroGen in a research note on Thursday, March 29th. BidaskClub upgraded FibroGen from a “hold” rating to a “buy” rating in a research note on Thursday, May 24th. Finally, ValuEngine raised FibroGen from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. FibroGen has a consensus rating of “Buy” and a consensus price target of $68.83.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.